Southern Acids (M) Berhad（SAB）株式概要投資持株会社であるサザン・アシッズ（M）ベルハドは、油脂化学製品の製造・販売に従事している。 詳細SAB ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績3/6財務の健全性5/6配当金3/6報酬当社が推定した公正価値より97.3%で取引されている リスク分析過去5年間で収益は年間22%減少しました。 すべてのリスクチェックを見るSAB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,236 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA487,236 investors already sharing narrativesYour Fair ValueRM Current PriceRM 3.0346.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture01b2016201920222025202620282031Revenue RM 959.9mEarnings RM 38.4mAdvancedSet Fair ValueView all narrativesSouthern Acids (M) Berhad 競合他社Hil Industries BerhadSymbol: KLSE:HILMarket cap: RM 215.8mAnalabs Resources BerhadSymbol: KLSE:ANALABSMarket cap: RM 194.0mFibromat (M) BerhadSymbol: KLSE:FIBROMarket cap: RM 189.9mPolymer Link Holdings BerhadSymbol: KLSE:POLYMERMarket cap: RM 103.6m価格と性能株価の高値、安値、推移の概要Southern Acids (M) Berhad過去の株価現在の株価RM 3.0352週高値RM 3.6052週安値RM 2.99ベータ0.221ヶ月の変化-2.26%3ヶ月変化-5.31%1年変化-10.88%3年間の変化-9.55%5年間の変化-21.91%IPOからの変化-36.34%最新ニュースDeclared Dividend • Jul 29Dividend of RM0.05 announcedDividend of RM0.05 is the same as last year. Ex-date: 15th October 2026 Payment date: 11th November 2026 Dividend yield will be 1.7%, which is lower than the industry average of 3.2%. Sustainability & Growth Dividend is well covered by both earnings (18% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.お知らせ • Jul 27+ 1 more updateSouthern Acids (M) Berhad, Annual General Meeting, Aug 28, 2026Southern Acids (M) Berhad, Annual General Meeting, Aug 28, 2026, at 11:00 Singapore Standard Time. Location: ballroom 3, level 1, wyndham acmar klang hotel, no. 1-g-1, jalan persiaran bukit raja 2/ku1, bandar baru klang, 41150 klang, selangor darul ehsan, MalaysiaReported Earnings • May 23Full year 2026 earnings released: EPS: RM0.27 (vs RM0.27 in FY 2025)Full year 2026 results: EPS: RM0.27 (up from RM0.27 in FY 2025). Revenue: RM918.9m (down 17% from FY 2025). Net income: RM37.4m (up 1.8% from FY 2025). Profit margin: 4.1% (up from 3.3% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.New Risk • Feb 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.9% Last year net profit margin: 3.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 21% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (1.9% net profit margin).Reported Earnings • Feb 24Third quarter 2026 earnings released: EPS: RM0.035 (vs RM0.18 in 3Q 2025)Third quarter 2026 results: EPS: RM0.035 (down from RM0.18 in 3Q 2025). Revenue: RM235.9m (down 22% from 3Q 2025). Net income: RM4.85m (down 81% from 3Q 2025). Profit margin: 2.1% (down from 8.2% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.New Risk • Nov 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RM410.8m (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RM410.8m market cap, or US$99.4m).最新情報をもっと見るRecent updatesDeclared Dividend • Jul 29Dividend of RM0.05 announcedDividend of RM0.05 is the same as last year. Ex-date: 15th October 2026 Payment date: 11th November 2026 Dividend yield will be 1.7%, which is lower than the industry average of 3.2%. Sustainability & Growth Dividend is well covered by both earnings (18% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.お知らせ • Jul 27+ 1 more updateSouthern Acids (M) Berhad, Annual General Meeting, Aug 28, 2026Southern Acids (M) Berhad, Annual General Meeting, Aug 28, 2026, at 11:00 Singapore Standard Time. Location: ballroom 3, level 1, wyndham acmar klang hotel, no. 1-g-1, jalan persiaran bukit raja 2/ku1, bandar baru klang, 41150 klang, selangor darul ehsan, MalaysiaReported Earnings • May 23Full year 2026 earnings released: EPS: RM0.27 (vs RM0.27 in FY 2025)Full year 2026 results: EPS: RM0.27 (up from RM0.27 in FY 2025). Revenue: RM918.9m (down 17% from FY 2025). Net income: RM37.4m (up 1.8% from FY 2025). Profit margin: 4.1% (up from 3.3% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.New Risk • Feb 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.9% Last year net profit margin: 3.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 21% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (1.9% net profit margin).Reported Earnings • Feb 24Third quarter 2026 earnings released: EPS: RM0.035 (vs RM0.18 in 3Q 2025)Third quarter 2026 results: EPS: RM0.035 (down from RM0.18 in 3Q 2025). Revenue: RM235.9m (down 22% from 3Q 2025). Net income: RM4.85m (down 81% from 3Q 2025). Profit margin: 2.1% (down from 8.2% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.New Risk • Nov 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RM410.8m (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RM410.8m market cap, or US$99.4m).Reported Earnings • Nov 20Second quarter 2026 earnings released: EPS: RM0.068 (vs RM0.038 in 2Q 2025)Second quarter 2026 results: EPS: RM0.068 (up from RM0.038 in 2Q 2025). Revenue: RM255.1m (down 14% from 2Q 2025). Net income: RM9.29m (up 80% from 2Q 2025). Profit margin: 3.6% (up from 1.7% in 2Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Oct 09Upcoming dividend of RM0.05 per shareEligible shareholders must have bought the stock before 16 October 2025. Payment date: 11 November 2025. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Malaysian dividend payers (5.4%). Lower than average of industry peers (3.0%).分析記事 • Sep 12Southern Acids (M) Berhad (KLSE:SAB) Is Due To Pay A Dividend Of MYR0.05Southern Acids (M) Berhad's ( KLSE:SAB ) investors are due to receive a payment of MYR0.05 per share on 11th of...お知らせ • Sep 05Kong Global Capital Sdn. Bhd. completed the acquisition of an unknown minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB).Kong Global Capital Sdn. Bhd. agreed to acquire an unknown minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB) on March 24, 2025. In a related transaction, Lim Wei Chuen also finalized an agreement to acquire an unknown minority stake in Pke (Malaysia) Sdn Bhd. Together, these disposals involved the sale of 936,500 shares to Lim Wei Chuen and 36,250 shares to Kong Global Capital Sdn Bhd. Kong Global Capital Sdn. Bhd. completed the acquisition of an unknown minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB) on August 27, 2025.お知らせ • Sep 04Lim Wei Chuen completed the acquisition of minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB).Lim Wei Chuen entered into a share sale agreement to acquire an unknown minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB) on March 24, 2025. In a related transaction, Kong Global Capital Sdn Bhd also finalized an agreement to acquire an unknown minority stake in Pke (Malaysia) Sdn Bhd. Together, these disposals involved the sale of 936,500 shares to Lim Wei Chuen and 36,250 shares to Kong Global Capital Sdn Bhd. Lim Wei Chuen completed the acquisition of minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB) on July 15, 2025.Reported Earnings • Aug 31First quarter 2026 earnings released: RM0.002 loss per share (vs RM0.012 profit in 1Q 2025)First quarter 2026 results: RM0.002 loss per share (down from RM0.012 profit in 1Q 2025). Revenue: RM226.1m (down 6.2% from 1Q 2025). Net loss: RM321.0k (down 119% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.分析記事 • Aug 29Southern Acids (M) Berhad (KLSE:SAB) Has Affirmed Its Dividend Of MYR0.05The board of Southern Acids (M) Berhad ( KLSE:SAB ) has announced that it will pay a dividend of MYR0.05 per share on...分析記事 • Aug 22Shareholders Will Probably Hold Off On Increasing Southern Acids (M) Berhad's (KLSE:SAB) CEO Compensation For The Time BeingKey Insights Southern Acids (M) Berhad's Annual General Meeting to take place on 29th of August Salary of RM518.4k is...Reported Earnings • Jul 31Full year 2025 earnings released: EPS: RM0.27 (vs RM0.10 in FY 2024)Full year 2025 results: EPS: RM0.27 (up from RM0.10 in FY 2024). Revenue: RM1.11b (up 20% from FY 2024). Net income: RM36.7m (up 169% from FY 2024). Profit margin: 3.3% (up from 1.5% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.分析記事 • Jul 30Southern Acids (M) Berhad (KLSE:SAB) Has Announced A Dividend Of MYR0.05Southern Acids (M) Berhad's ( KLSE:SAB ) investors are due to receive a payment of MYR0.05 per share on 11th of...Declared Dividend • Jul 30Dividend of RM0.05 announcedDividend of RM0.05 is the same as last year. Ex-date: 16th October 2025 Payment date: 11th November 2025 Dividend yield will be 1.5%, which is lower than the industry average of 3.2%. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (39% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. Earnings per share has grown by 2.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Jul 28Southern Acids (M) Berhad, Annual General Meeting, Aug 29, 2025Southern Acids (M) Berhad, Annual General Meeting, Aug 29, 2025, at 11:30 Singapore Standard Time. Location: ballroom 3, level 1, wyndham acmar klang hotel, no. 1-g-1, jalan persiaran bukit raja 2/ku1, bandar baru klang, 41150 klang, selangor darul ehsan, MalaysiaReported Earnings • May 30Full year 2025 earnings released: EPS: RM0.27 (vs RM0.10 in FY 2024)Full year 2025 results: EPS: RM0.27 (up from RM0.10 in FY 2024). Revenue: RM1.09b (up 19% from FY 2024). Net income: RM36.7m (up 169% from FY 2024). Profit margin: 3.4% (up from 1.5% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Feb 20Third quarter 2025 earnings released: EPS: RM0.18 (vs RM0.033 in 3Q 2024)Third quarter 2025 results: EPS: RM0.18 (up from RM0.033 in 3Q 2024). Revenue: RM303.1m (up 30% from 3Q 2024). Net income: RM25.0m (up 447% from 3Q 2024). Profit margin: 8.2% (up from 2.0% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 27Second quarter 2025 earnings released: EPS: RM0.038 (vs RM0.039 loss in 2Q 2024)Second quarter 2025 results: EPS: RM0.038 (up from RM0.039 loss in 2Q 2024). Revenue: RM298.1m (up 28% from 2Q 2024). Net income: RM5.16m (up RM10.5m from 2Q 2024). Profit margin: 1.7% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.New Risk • Oct 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RM430.0m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.7% net profit margin). Market cap is less than US$100m (RM430.0m market cap, or US$99.9m).Upcoming Dividend • Oct 10Upcoming dividend of RM0.05 per shareEligible shareholders must have bought the stock before 17 October 2024. Payment date: 11 November 2024. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 1.6%. Lower than top quartile of Malaysian dividend payers (4.7%). Lower than average of industry peers (2.0%).New Risk • Aug 24New major risk - Revenue and earnings growthEarnings have declined by 4.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.7% net profit margin). Market cap is less than US$100m (RM431.3m market cap, or US$98.6m).Reported Earnings • Jul 30Full year 2024 earnings released: EPS: RM0.10 (vs RM0.24 in FY 2023)Full year 2024 results: EPS: RM0.10 (down from RM0.24 in FY 2023). Revenue: RM920.2m (down 17% from FY 2023). Net income: RM13.6m (down 59% from FY 2023). Profit margin: 1.5% (down from 3.0% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • Jul 25Southern Acids (M) Berhad, Annual General Meeting, Aug 26, 2024Southern Acids (M) Berhad, Annual General Meeting, Aug 26, 2024, at 11:30 Singapore Standard Time. Location: level 29, centro tower, the edison board room, no.8, jalan batu tiga lama, 41300 klang, selangor darul ehsan, MalaysiaNew Risk • Jun 25New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RM468.3m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (1.5% net profit margin). Market cap is less than US$100m (RM468.3m market cap, or US$99.5m).Reported Earnings • Jun 04Full year 2024 earnings released: EPS: RM0.10 (vs RM0.24 in FY 2023)Full year 2024 results: EPS: RM0.10 (down from RM0.24 in FY 2023). Revenue: RM908.0m (down 18% from FY 2023). Net income: RM13.9m (down 58% from FY 2023). Profit margin: 1.5% (down from 3.0% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.お知らせ • Mar 21Southern Acids (M) Berhad Announces Redesignation of Chung Kin Mun from Independent Director to Non Independent and Non Executive DirectorSouthern Acids (M) Berhad announced redesignation of Mr. Chung Kin Mun from previous position of Independent Director to new position Non Independent and Non Executive Director. Date of change is 20 March 2024, age is 56, gender is male, nationality is Malaysia.Reported Earnings • Mar 02Third quarter 2024 earnings released: EPS: RM0.033 (vs RM0.12 in 3Q 2023)Third quarter 2024 results: EPS: RM0.033 (down from RM0.12 in 3Q 2023). Revenue: RM232.6m (down 16% from 3Q 2023). Net income: RM4.57m (down 73% from 3Q 2023). Profit margin: 2.0% (down from 6.1% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • Feb 29+ 3 more updatesSouthern Acids (M) Berhad Announces Redesignation of Stephen Wan Yeng Leong from Member of Audit Committee to Independent and Non Executive Chairman of Audit CommitteeSouthern Acids (M) Berhad announced Redesignation of Mr. Stephen Wan Yeng Leong from Member of Audit Committee to Independent and Non Executive Chairman of Audit Committee. Age is 56. Date of change is 29 February 2024. Composition of Audit Committee (Name and Directorate of members after change): Mr. Stephen Wan Yeng Leong (Independent Non Executive Director/Chairman); Mr. Chung Kin Mun (Senior Independent Non Executive Director/Member) and Madam Deborah Deb-bie Choa (Independent Non Executive Director/Member).お知らせ • Feb 09Southern Acids (M) Berhad (KLSE:SAB) entered into agreement to acquire remaining 10% stake in Firstview Development Sdn Bhd from Low Mong Hua Sdn Berhad for RM 23.5 million.Southern Acids (M) Berhad (KLSE:SAB) entered into agreement to acquire remaining 10% stake in Firstview Development Sdn Bhd from Low Mong Hua Sdn Berhad for RM 23.5 million on February 8, 2024. Consideration consist of an intial payment of RM 1.5 million upon signing the agreement second payment of RM 4.5 million upon completion of share transfer third payment of RM 4.5 million on or before March 1, 2025 fourth payment of RM 4.5 million on or before March 1, 2026 fifth payment of RM 4.5 million on or before March 1, 2027 and last payment of RM 4 million on or before March 1, 2028. The transaction is expected to close at the end of February 2024.Reported Earnings • Nov 29Second quarter 2024 earnings released: RM0.039 loss per share (vs RM0.081 profit in 2Q 2023)Second quarter 2024 results: RM0.039 loss per share (down from RM0.081 profit in 2Q 2023). Revenue: RM232.5m (down 17% from 2Q 2023). Net loss: RM5.38m (down 148% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 5% per year.Upcoming Dividend • Sep 26Upcoming dividend of RM0.05 per share at 1.5% yieldEligible shareholders must have bought the stock before 03 October 2023. Payment date: 26 October 2023. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Malaysian dividend payers (5.0%). Lower than average of industry peers (3.8%).お知らせ • Aug 31Southern Acids (M) Berhad Announces Appointment of Deborah Deb-Bie Choa as Independent and Non Executive DirectorSouthern Acids (M) Berhad announced appointment of Madam Deborah Deb-Bie Choa as Independent and Non Executive Director. Age 52, Date of change 30 August 2023. Qualifications: Others-Barrister at Law of England and Wales-The Honourable Society of Lincoln's Inn, Degree-Bachelor of Laws LLB Law-University of Leicester. Working experience: Madam Deborah started her career as a lawyer, for the first 3 years in litigation followed by 16 years in the corporate field. As a partner in a boutique leading law firm, her areas of practice extended to cover Corporate Finance, Capital Markets (Islamic & Conventional), Mergers & Acquisitions, Debt Restructuring, General Corporate & Commercial. From 2015 until early 2022, she was part of the founding team of Projek57, an award-winning accredited social enterprise which aspires to influence youths from multicultural backgrounds with nation building values, as well as empower the underprivileged. Since April 2022, she rejoined legal practice as the Chief Operating Officer of the law firm of Adnan Sundra & Low where she is able to combine her legal experience with management. She also focuses on exploring ways to enhance the practice of the firm including enhancing efficiency and overall capability and formulating their business strategies.Reported Earnings • Aug 30First quarter 2024 earnings released: EPS: RM0.067 (vs RM0.11 in 1Q 2023)First quarter 2024 results: EPS: RM0.067 (down from RM0.11 in 1Q 2023). Revenue: RM215.3m (down 28% from 1Q 2023). Net income: RM9.13m (down 39% from 1Q 2023). Profit margin: 4.2% (down from 5.0% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.New Risk • Aug 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RM457.4m (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (3.0% net profit margin). Market cap is less than US$100m (RM457.4m market cap, or US$99.7m).Reported Earnings • Jul 30Full year 2023 earnings released: EPS: RM0.24 (vs RM0.69 in FY 2022)Full year 2023 results: EPS: RM0.24 (down from RM0.69 in FY 2022). Revenue: RM1.11b (down 6.3% from FY 2022). Net income: RM33.3m (down 65% from FY 2022). Profit margin: 3.0% (down from 8.0% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Jul 29+ 1 more updateSouthern Acids (M) Berhad, Annual General Meeting, Aug 30, 2023Southern Acids (M) Berhad, Annual General Meeting, Aug 30, 2023, at 14:30 Singapore Standard Time. Agenda: To receive the Audited Financial Statements for the financial year ended 31 March 2023 together with the Reports of the Directors and Auditors thereon. to approve the payment of Single Tier Final Dividend of 5 sen per ordinary share in respect of the financial year ended 31 March 2023; to approve the payment of Directors' fees amounting to RM540,986 for the financial year ended 31 March 2023; to approve the payment of Directors' Benefits up to an amount of RM250,000 for the period from 31 August 2023 until the next AGM of the Company to be held in 2024; to re-elect Mr Chung Kin Mun who is retiring under Clause 113 of the Company's Constitution, and being eligible, has offered himself for re-election; and to transact other business.お知らせ • Jun 02+ 2 more updatesSouthern Acids (M) Berhad Announces Cessation of Office of Madam Leong So Seh as Member of Nomination and Remuneration CommitteeSouthern Acids (M) Berhad announced cessation of office of Madam Leong So Seh as Member of Nomination and Remuneration Committee with effect from June 1, 2023. Age: 71. Gender: Female. Nationality: Malaysia. Directorate: Independent and Non Executive. Composition of Nomination and Remuneration Committee(Name and Directorate of members after change): Chung Kin Mun (Senior Independent Non Executive Director/Chairman); Tan Sri Datuk Seri Panglima Sulong bin Matjeraie (Independent Non Executive Director/Member); Stephen Wan Yeng Leong (Independent Non Executive Director/Member).Reported Earnings • May 27Full year 2023 earnings released: EPS: RM0.24 (vs RM0.69 in FY 2022)Full year 2023 results: EPS: RM0.24 (down from RM0.69 in FY 2022). Revenue: RM1.10b (down 6.9% from FY 2022). Net income: RM33.3m (down 65% from FY 2022). Profit margin: 3.0% (down from 8.0% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • May 27+ 2 more updatesOuthern Acids (M) Berhad Recommends Single Tier Final Dividend in Respect of the Financial Year Ended 31 March 2023Southern Acids (M) Berhad recommended a Single Tier Final Dividend of 5.0 sen per ordinary share, amounting to a total payout of RM6,846,706.60 in respect of the financial year ended 31 March 2023. This dividend proposal is subject to the approval by shareholders at the forthcoming Annual General Meeting of the Company.分析記事 • Mar 03Southern Acids (M) Berhad's (KLSE:SAB) Soft Earnings Are Actually Better Than They AppearSoft earnings didn't appear to concern Southern Acids (M) Berhad's ( KLSE:SAB ) shareholders over the last week. We did...Reported Earnings • Feb 25Third quarter 2023 earnings released: EPS: RM0.12 (vs RM0.20 in 3Q 2022)Third quarter 2023 results: EPS: RM0.12 (down from RM0.20 in 3Q 2022). Revenue: RM275.9m (down 10% from 3Q 2022). Net income: RM16.8m (down 38% from 3Q 2022). Profit margin: 6.1% (down from 8.8% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 25Second quarter 2023 earnings released: EPS: RM0.082 (vs RM0.13 in 2Q 2022)Second quarter 2023 results: EPS: RM0.082 (down from RM0.13 in 2Q 2022). Revenue: RM280.1m (up 14% from 2Q 2022). Net income: RM11.2m (down 35% from 2Q 2022). Profit margin: 4.0% (down from 6.9% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Price Target Changed • Nov 16Price target decreased to RM3.40Down from RM3.68, the current price target is provided by 1 analyst. New target price is 8.1% below last closing price of RM3.70. Stock is down 2.6% over the past year. The company posted earnings per share of RM0.69 last year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. MD & Non-Independent Executive Director Nick Low was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Nov 01Upcoming dividend of RM0.05 per shareEligible shareholders must have bought the stock before 08 November 2022. Payment date: 28 November 2022. Payout ratio is a comfortable 8.0% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Malaysian dividend payers (5.3%). Lower than average of industry peers (5.6%).Reported Earnings • Aug 02Full year 2022 earnings released: EPS: RM0.69 (vs RM0.27 in FY 2021)Full year 2022 results: EPS: RM0.69 (up from RM0.27 in FY 2021). Revenue: RM1.18b (up 58% from FY 2021). Net income: RM94.4m (up 153% from FY 2021). Profit margin: 8.0% (up from 5.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Jul 30+ 1 more updateSouthern Acids (M) Berhad Announces Final Dividend, Payable on 28 Nov. 2022Southern Acids (M) Berhad announced a final dividend of MYR 0.0500 per share for the year March 31, 2022. Ex-date is on 08 Nov. 2022 and the Payment date is on 28 Nov. 2022.お知らせ • May 20Southern Acids (M) Berhad Recommends Single Tier Final Dividend for the Financial Year Ended March 31, 2022Southern Acids (M) Berhad announced that its Board of Directors had recommended a Single Tier Final Dividend of 5.0 sen per ordinary share, amounting to a total payout of MYR 6,846,706.60 in respect of the financial year ended March 31, 2022. This dividend proposal is subject to the approval by shareholders at the upcoming Annual General Meeting of the Company.Reported Earnings • May 20Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2022 results: EPS: RM0.69 (up from RM0.27 in FY 2021). Revenue: RM1.18b (up 58% from FY 2021). Net income: RM94.5m (up 153% from FY 2021). Profit margin: 8.0% (up from 5.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.2%. Earnings per share (EPS) exceeded analyst estimates by 11%. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Price Target Changed • Apr 27Price target decreased to RM3.40Down from RM3.68, the current price target is provided by 1 analyst. New target price is 13% below last closing price of RM3.89. Stock is up 3.2% over the past year. The company posted earnings per share of RM0.27 last year.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. MD & Non-Independent Executive Director Nick Low was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 27Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: EPS: RM0.20 (up from RM0.041 in 3Q 2021). Revenue: RM307.2m (up 66% from 3Q 2021). Net income: RM27.2m (up 387% from 3Q 2021). Profit margin: 8.8% (up from 3.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.2%. Earnings per share (EPS) exceeded analyst estimates by 11%. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 29Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: EPS: RM0.13 (up from RM0.06 in 2Q 2021). Revenue: RM246.7m (up 41% from 2Q 2021). Net income: RM17.1m (up 110% from 2Q 2021). Profit margin: 6.9% (up from 4.7% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.2%. Earnings per share (EPS) exceeded analyst estimates by 11%. Earnings per share (EPS) surpassed analyst estimates by 11%. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Reported Earnings • Sep 22First quarter 2022 earnings released: EPS RM0.17 (vs RM0.13 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: RM258.0m (up 63% from 1Q 2021). Net income: RM23.5m (up 37% from 1Q 2021). Profit margin: 9.1% (down from 11% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Upcoming Dividend • Aug 26Upcoming dividend of RM0.05 per shareEligible shareholders must have bought the stock before 02 September 2021. Payment date: 24 September 2021. Trailing yield: 1.3%. Lower than top quartile of Malaysian dividend payers (4.1%). Lower than average of industry peers (1.8%).Reported Earnings • Aug 03Full year 2021 earnings released: EPS RM0.27 (vs RM0.23 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: RM745.9m (up 12% from FY 2020). Net income: RM37.4m (up 17% from FY 2020). Profit margin: 5.0% (up from 4.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Price Target Changed • Jul 30Price target decreased to RM3.40Down from RM3.68, the current price target is provided by 1 analyst. New target price is 12% below last closing price of RM3.85. Stock is up 6.6% over the past year.Reported Earnings • May 28Full year 2021 earnings released: EPS RM0.27 (vs RM0.23 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: RM741.1m (up 11% from FY 2020). Net income: RM37.4m (up 17% from FY 2020). Profit margin: 5.0% (up from 4.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.分析記事 • May 27If You Like EPS Growth Then Check Out Southern Acids (M) Berhad (KLSE:SAB) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...お知らせ • May 26Southern Acids (M) Berhad Recommends Final Dividend for the Year Ended March 31, 2021Board of Directors of Southern Acids (M) Berhad had recommended a Single Tier Final Dividend of 5.0 sen per ordinary share, amounting to a total payout of MYR 6,846,706.60 in respect of the financial year ended 31 March 2021. This dividend proposal is subject to the approval by shareholders at the forthcoming Annual General Meeting of the Company.分析記事 • Apr 19The Returns At Southern Acids (M) Berhad (KLSE:SAB) Aren't GrowingTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...Reported Earnings • Feb 27Third quarter 2021 earnings released: EPS RM0.041 (vs RM0.076 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: RM185.6m (up 8.4% from 3Q 2020). Net income: RM5.58m (down 47% from 3Q 2020). Profit margin: 3.0% (down from 6.1% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.分析記事 • Feb 24Are Strong Financial Prospects The Force That Is Driving The Momentum In Southern Acids (M) Berhad's KLSE:SAB) Stock?Most readers would already be aware that Southern Acids (M) Berhad's (KLSE:SAB) stock increased significantly by 6.1...分析記事 • Jan 13Returns On Capital At Southern Acids (M) Berhad (KLSE:SAB) Paint An Interesting PictureFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...分析記事 • Dec 15What Can We Learn About Southern Acids (M) Berhad's (KLSE:SAB) CEO Compensation?This article will reflect on the compensation paid to Nick Low who has served as CEO of Southern Acids (M) Berhad...Is New 90 Day High Low • Dec 14New 90-day high: RM3.88The company is up 7.0% from its price of RM3.61 on 15 September 2020. The Malaysian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 35% over the same period.お知らせ • Nov 27Southern Acids (M) Berhad Announces Appointment of Tan Sri Datuk Seri Panglima Sulong Bin Matjeraie as Independent and Non Executive Ember of Audit CommitteeSouthern Acids (M) Berhad announced appointment of Tan Sri Datuk Seri Panglima Sulong Bin Matjeraie as Independent and Non Executive ember of Audit Committee. Date of change is November 26, 2020.Reported Earnings • Nov 27Second quarter 2021 earnings released: EPS RM0.06The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: RM174.7m (up 4.7% from 2Q 2020). Net income: RM8.15m (up 6.0% from 2Q 2020). Profit margin: 4.7% (up from 4.6% in 2Q 2020). The increase in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year.分析記事 • Nov 24Southern Acids (M) Berhad (KLSE:SAB) Share Prices Have Dropped 14% In The Last Three YearsIn order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...Is New 90 Day High Low • Nov 17New 90-day high: RM3.80The company is up 3.0% from its price of RM3.70 on 18 August 2020. The Malaysian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 10.0% over the same period.お知らせ • Sep 26+ 1 more updateSouthern Acids (M) Berhad Announces the Resignation of Encik Teo Leng as Independent and Non Executive Member of Audit CommitteeSouthern Acids (M) Berhad announced the resignation of Encik Teo Leng as Independent and Non Executive Member of Audit Committee. The resignation was effective on September 25, 2020.Is New 90 Day High Low • Sep 24New 90-day high: RM3.72The company is up 9.0% from its price of RM3.41 on 25 June 2020. The Malaysian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 6.0% over the same period.Upcoming Dividend • Sep 24Upcoming Dividend of RM0.05 Per ShareWill be paid on the 23rd of October to those who are registered shareholders by the 1st of October. The trailing yield of 1.3% is below the top quartile of Malaysian dividend payers (5.0%), and is lower than industry peers (2.2%).株主還元SABMY ChemicalsMY 市場7D0.3%0.8%1.3%1Y-10.9%12.9%9.8%株主還元を見る業界別リターン: SAB過去 1 年間で12.9 % の収益を上げたMY Chemicals業界を下回りました。リターン対市場: SABは、過去 1 年間で9.8 % のリターンを上げたMY市場を下回りました。価格変動Is SAB's price volatile compared to industry and market?SAB volatilitySAB Average Weekly Movementn/aChemicals Industry Average Movement6.4%Market Average Movement5.5%10% most volatile stocks in MY Market11.8%10% least volatile stocks in MY Market2.4%安定した株価: データは利用できません。時間の経過による変動: 過去 1 年間のSABのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19801,676Nick Lowwww.southernacids.com投資持株会社であるサザン・アシッズ（M）ベルハドは、油脂化学製品の製造・販売を行っている。同社は3つのセグメントで事業を展開している：オレオケミカル製造、製粉・栽培、ヘルスケア・サービス。同社は、パーソナルケア、洗浄剤、食品など様々な用途に使用される脂肪酸とグリセリンを製造・販売している。同社はまた、新鮮な果房から粗パーム油とパーム核への加工、およびアブラヤシの栽培事業にも携わっている。さらに、クランで232床の私立三次病院を運営し、心臓病学、手外科・小外科、腎臓病学、神経外科、整形外科、産婦人科、放射線治療、腫瘍学サービス、E N.T.、頭頸部外科、手外科・小外科、腎臓病学、神経学、整形外科、産婦人科、放射線治療・腫瘍学サービスを提供している。さらに、同社は管理・会計、オーバーヘッドコンベア商品積み込みサービスを提供し、不動産開発と病院建物のリースも行っている。マレーシア、インドネシア、その他のアジア、欧州、米国、および国際的に事業を展開している。サザン・アシッズ（M）ベルハドは1980年に設立され、マレーシアのクランに本社を置く。もっと見るSouthern Acids (M) Berhad 基礎のまとめSouthern Acids (M) Berhad の収益と売上を時価総額と比較するとどうか。SAB 基礎統計学時価総額RM 414.91m収益（TTM）RM 37.38m売上高(TTM)RM 933.56m11.1xPER（株価収益率0.4xP/SレシオSAB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SAB 損益計算書（TTM）収益RM 933.56m売上原価RM 722.80m売上総利益RM 210.76mその他の費用RM 173.38m収益RM 37.38m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.27グロス・マージン22.58%純利益率4.00%有利子負債／自己資本比率1.1%SAB の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.7%現在の配当利回り18%配当性向SAB 配当は確実ですか？SAB 配当履歴とベンチマークを見るSAB 、いつまでに購入すれば配当金を受け取れますか？Southern Acids (M) Berhad 配当日配当落ち日Oct 15 2026配当支払日Nov 11 2026配当落ちまでの日数70 days配当支払日までの日数97 daysSAB 配当は確実ですか？SAB 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/05 17:34終値2026/08/05 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Southern Acids (M) Berhad 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Yee Ping VoonKenanga ResearchLee HoeRHB Investment Bank
Declared Dividend • Jul 29Dividend of RM0.05 announcedDividend of RM0.05 is the same as last year. Ex-date: 15th October 2026 Payment date: 11th November 2026 Dividend yield will be 1.7%, which is lower than the industry average of 3.2%. Sustainability & Growth Dividend is well covered by both earnings (18% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.
お知らせ • Jul 27+ 1 more updateSouthern Acids (M) Berhad, Annual General Meeting, Aug 28, 2026Southern Acids (M) Berhad, Annual General Meeting, Aug 28, 2026, at 11:00 Singapore Standard Time. Location: ballroom 3, level 1, wyndham acmar klang hotel, no. 1-g-1, jalan persiaran bukit raja 2/ku1, bandar baru klang, 41150 klang, selangor darul ehsan, Malaysia
Reported Earnings • May 23Full year 2026 earnings released: EPS: RM0.27 (vs RM0.27 in FY 2025)Full year 2026 results: EPS: RM0.27 (up from RM0.27 in FY 2025). Revenue: RM918.9m (down 17% from FY 2025). Net income: RM37.4m (up 1.8% from FY 2025). Profit margin: 4.1% (up from 3.3% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
New Risk • Feb 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.9% Last year net profit margin: 3.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 21% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (1.9% net profit margin).
Reported Earnings • Feb 24Third quarter 2026 earnings released: EPS: RM0.035 (vs RM0.18 in 3Q 2025)Third quarter 2026 results: EPS: RM0.035 (down from RM0.18 in 3Q 2025). Revenue: RM235.9m (down 22% from 3Q 2025). Net income: RM4.85m (down 81% from 3Q 2025). Profit margin: 2.1% (down from 8.2% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
New Risk • Nov 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RM410.8m (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RM410.8m market cap, or US$99.4m).
Declared Dividend • Jul 29Dividend of RM0.05 announcedDividend of RM0.05 is the same as last year. Ex-date: 15th October 2026 Payment date: 11th November 2026 Dividend yield will be 1.7%, which is lower than the industry average of 3.2%. Sustainability & Growth Dividend is well covered by both earnings (18% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.
お知らせ • Jul 27+ 1 more updateSouthern Acids (M) Berhad, Annual General Meeting, Aug 28, 2026Southern Acids (M) Berhad, Annual General Meeting, Aug 28, 2026, at 11:00 Singapore Standard Time. Location: ballroom 3, level 1, wyndham acmar klang hotel, no. 1-g-1, jalan persiaran bukit raja 2/ku1, bandar baru klang, 41150 klang, selangor darul ehsan, Malaysia
Reported Earnings • May 23Full year 2026 earnings released: EPS: RM0.27 (vs RM0.27 in FY 2025)Full year 2026 results: EPS: RM0.27 (up from RM0.27 in FY 2025). Revenue: RM918.9m (down 17% from FY 2025). Net income: RM37.4m (up 1.8% from FY 2025). Profit margin: 4.1% (up from 3.3% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
New Risk • Feb 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.9% Last year net profit margin: 3.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 21% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (1.9% net profit margin).
Reported Earnings • Feb 24Third quarter 2026 earnings released: EPS: RM0.035 (vs RM0.18 in 3Q 2025)Third quarter 2026 results: EPS: RM0.035 (down from RM0.18 in 3Q 2025). Revenue: RM235.9m (down 22% from 3Q 2025). Net income: RM4.85m (down 81% from 3Q 2025). Profit margin: 2.1% (down from 8.2% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
New Risk • Nov 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RM410.8m (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Market cap is less than US$100m (RM410.8m market cap, or US$99.4m).
Reported Earnings • Nov 20Second quarter 2026 earnings released: EPS: RM0.068 (vs RM0.038 in 2Q 2025)Second quarter 2026 results: EPS: RM0.068 (up from RM0.038 in 2Q 2025). Revenue: RM255.1m (down 14% from 2Q 2025). Net income: RM9.29m (up 80% from 2Q 2025). Profit margin: 3.6% (up from 1.7% in 2Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Oct 09Upcoming dividend of RM0.05 per shareEligible shareholders must have bought the stock before 16 October 2025. Payment date: 11 November 2025. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Malaysian dividend payers (5.4%). Lower than average of industry peers (3.0%).
分析記事 • Sep 12Southern Acids (M) Berhad (KLSE:SAB) Is Due To Pay A Dividend Of MYR0.05Southern Acids (M) Berhad's ( KLSE:SAB ) investors are due to receive a payment of MYR0.05 per share on 11th of...
お知らせ • Sep 05Kong Global Capital Sdn. Bhd. completed the acquisition of an unknown minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB).Kong Global Capital Sdn. Bhd. agreed to acquire an unknown minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB) on March 24, 2025. In a related transaction, Lim Wei Chuen also finalized an agreement to acquire an unknown minority stake in Pke (Malaysia) Sdn Bhd. Together, these disposals involved the sale of 936,500 shares to Lim Wei Chuen and 36,250 shares to Kong Global Capital Sdn Bhd. Kong Global Capital Sdn. Bhd. completed the acquisition of an unknown minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB) on August 27, 2025.
お知らせ • Sep 04Lim Wei Chuen completed the acquisition of minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB).Lim Wei Chuen entered into a share sale agreement to acquire an unknown minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB) on March 24, 2025. In a related transaction, Kong Global Capital Sdn Bhd also finalized an agreement to acquire an unknown minority stake in Pke (Malaysia) Sdn Bhd. Together, these disposals involved the sale of 936,500 shares to Lim Wei Chuen and 36,250 shares to Kong Global Capital Sdn Bhd. Lim Wei Chuen completed the acquisition of minority stake in Pke (Malaysia) Sdn Bhd from Southern Acids (M) Berhad (KLSE:SAB) on July 15, 2025.
Reported Earnings • Aug 31First quarter 2026 earnings released: RM0.002 loss per share (vs RM0.012 profit in 1Q 2025)First quarter 2026 results: RM0.002 loss per share (down from RM0.012 profit in 1Q 2025). Revenue: RM226.1m (down 6.2% from 1Q 2025). Net loss: RM321.0k (down 119% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
分析記事 • Aug 29Southern Acids (M) Berhad (KLSE:SAB) Has Affirmed Its Dividend Of MYR0.05The board of Southern Acids (M) Berhad ( KLSE:SAB ) has announced that it will pay a dividend of MYR0.05 per share on...
分析記事 • Aug 22Shareholders Will Probably Hold Off On Increasing Southern Acids (M) Berhad's (KLSE:SAB) CEO Compensation For The Time BeingKey Insights Southern Acids (M) Berhad's Annual General Meeting to take place on 29th of August Salary of RM518.4k is...
Reported Earnings • Jul 31Full year 2025 earnings released: EPS: RM0.27 (vs RM0.10 in FY 2024)Full year 2025 results: EPS: RM0.27 (up from RM0.10 in FY 2024). Revenue: RM1.11b (up 20% from FY 2024). Net income: RM36.7m (up 169% from FY 2024). Profit margin: 3.3% (up from 1.5% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
分析記事 • Jul 30Southern Acids (M) Berhad (KLSE:SAB) Has Announced A Dividend Of MYR0.05Southern Acids (M) Berhad's ( KLSE:SAB ) investors are due to receive a payment of MYR0.05 per share on 11th of...
Declared Dividend • Jul 30Dividend of RM0.05 announcedDividend of RM0.05 is the same as last year. Ex-date: 16th October 2025 Payment date: 11th November 2025 Dividend yield will be 1.5%, which is lower than the industry average of 3.2%. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (39% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. Earnings per share has grown by 2.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Jul 28Southern Acids (M) Berhad, Annual General Meeting, Aug 29, 2025Southern Acids (M) Berhad, Annual General Meeting, Aug 29, 2025, at 11:30 Singapore Standard Time. Location: ballroom 3, level 1, wyndham acmar klang hotel, no. 1-g-1, jalan persiaran bukit raja 2/ku1, bandar baru klang, 41150 klang, selangor darul ehsan, Malaysia
Reported Earnings • May 30Full year 2025 earnings released: EPS: RM0.27 (vs RM0.10 in FY 2024)Full year 2025 results: EPS: RM0.27 (up from RM0.10 in FY 2024). Revenue: RM1.09b (up 19% from FY 2024). Net income: RM36.7m (up 169% from FY 2024). Profit margin: 3.4% (up from 1.5% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Feb 20Third quarter 2025 earnings released: EPS: RM0.18 (vs RM0.033 in 3Q 2024)Third quarter 2025 results: EPS: RM0.18 (up from RM0.033 in 3Q 2024). Revenue: RM303.1m (up 30% from 3Q 2024). Net income: RM25.0m (up 447% from 3Q 2024). Profit margin: 8.2% (up from 2.0% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 27Second quarter 2025 earnings released: EPS: RM0.038 (vs RM0.039 loss in 2Q 2024)Second quarter 2025 results: EPS: RM0.038 (up from RM0.039 loss in 2Q 2024). Revenue: RM298.1m (up 28% from 2Q 2024). Net income: RM5.16m (up RM10.5m from 2Q 2024). Profit margin: 1.7% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
New Risk • Oct 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RM430.0m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.7% net profit margin). Market cap is less than US$100m (RM430.0m market cap, or US$99.9m).
Upcoming Dividend • Oct 10Upcoming dividend of RM0.05 per shareEligible shareholders must have bought the stock before 17 October 2024. Payment date: 11 November 2024. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 1.6%. Lower than top quartile of Malaysian dividend payers (4.7%). Lower than average of industry peers (2.0%).
New Risk • Aug 24New major risk - Revenue and earnings growthEarnings have declined by 4.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.7% net profit margin). Market cap is less than US$100m (RM431.3m market cap, or US$98.6m).
Reported Earnings • Jul 30Full year 2024 earnings released: EPS: RM0.10 (vs RM0.24 in FY 2023)Full year 2024 results: EPS: RM0.10 (down from RM0.24 in FY 2023). Revenue: RM920.2m (down 17% from FY 2023). Net income: RM13.6m (down 59% from FY 2023). Profit margin: 1.5% (down from 3.0% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 25Southern Acids (M) Berhad, Annual General Meeting, Aug 26, 2024Southern Acids (M) Berhad, Annual General Meeting, Aug 26, 2024, at 11:30 Singapore Standard Time. Location: level 29, centro tower, the edison board room, no.8, jalan batu tiga lama, 41300 klang, selangor darul ehsan, Malaysia
New Risk • Jun 25New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RM468.3m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (1.5% net profit margin). Market cap is less than US$100m (RM468.3m market cap, or US$99.5m).
Reported Earnings • Jun 04Full year 2024 earnings released: EPS: RM0.10 (vs RM0.24 in FY 2023)Full year 2024 results: EPS: RM0.10 (down from RM0.24 in FY 2023). Revenue: RM908.0m (down 18% from FY 2023). Net income: RM13.9m (down 58% from FY 2023). Profit margin: 1.5% (down from 3.0% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 21Southern Acids (M) Berhad Announces Redesignation of Chung Kin Mun from Independent Director to Non Independent and Non Executive DirectorSouthern Acids (M) Berhad announced redesignation of Mr. Chung Kin Mun from previous position of Independent Director to new position Non Independent and Non Executive Director. Date of change is 20 March 2024, age is 56, gender is male, nationality is Malaysia.
Reported Earnings • Mar 02Third quarter 2024 earnings released: EPS: RM0.033 (vs RM0.12 in 3Q 2023)Third quarter 2024 results: EPS: RM0.033 (down from RM0.12 in 3Q 2023). Revenue: RM232.6m (down 16% from 3Q 2023). Net income: RM4.57m (down 73% from 3Q 2023). Profit margin: 2.0% (down from 6.1% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 29+ 3 more updatesSouthern Acids (M) Berhad Announces Redesignation of Stephen Wan Yeng Leong from Member of Audit Committee to Independent and Non Executive Chairman of Audit CommitteeSouthern Acids (M) Berhad announced Redesignation of Mr. Stephen Wan Yeng Leong from Member of Audit Committee to Independent and Non Executive Chairman of Audit Committee. Age is 56. Date of change is 29 February 2024. Composition of Audit Committee (Name and Directorate of members after change): Mr. Stephen Wan Yeng Leong (Independent Non Executive Director/Chairman); Mr. Chung Kin Mun (Senior Independent Non Executive Director/Member) and Madam Deborah Deb-bie Choa (Independent Non Executive Director/Member).
お知らせ • Feb 09Southern Acids (M) Berhad (KLSE:SAB) entered into agreement to acquire remaining 10% stake in Firstview Development Sdn Bhd from Low Mong Hua Sdn Berhad for RM 23.5 million.Southern Acids (M) Berhad (KLSE:SAB) entered into agreement to acquire remaining 10% stake in Firstview Development Sdn Bhd from Low Mong Hua Sdn Berhad for RM 23.5 million on February 8, 2024. Consideration consist of an intial payment of RM 1.5 million upon signing the agreement second payment of RM 4.5 million upon completion of share transfer third payment of RM 4.5 million on or before March 1, 2025 fourth payment of RM 4.5 million on or before March 1, 2026 fifth payment of RM 4.5 million on or before March 1, 2027 and last payment of RM 4 million on or before March 1, 2028. The transaction is expected to close at the end of February 2024.
Reported Earnings • Nov 29Second quarter 2024 earnings released: RM0.039 loss per share (vs RM0.081 profit in 2Q 2023)Second quarter 2024 results: RM0.039 loss per share (down from RM0.081 profit in 2Q 2023). Revenue: RM232.5m (down 17% from 2Q 2023). Net loss: RM5.38m (down 148% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 5% per year.
Upcoming Dividend • Sep 26Upcoming dividend of RM0.05 per share at 1.5% yieldEligible shareholders must have bought the stock before 03 October 2023. Payment date: 26 October 2023. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Malaysian dividend payers (5.0%). Lower than average of industry peers (3.8%).
お知らせ • Aug 31Southern Acids (M) Berhad Announces Appointment of Deborah Deb-Bie Choa as Independent and Non Executive DirectorSouthern Acids (M) Berhad announced appointment of Madam Deborah Deb-Bie Choa as Independent and Non Executive Director. Age 52, Date of change 30 August 2023. Qualifications: Others-Barrister at Law of England and Wales-The Honourable Society of Lincoln's Inn, Degree-Bachelor of Laws LLB Law-University of Leicester. Working experience: Madam Deborah started her career as a lawyer, for the first 3 years in litigation followed by 16 years in the corporate field. As a partner in a boutique leading law firm, her areas of practice extended to cover Corporate Finance, Capital Markets (Islamic & Conventional), Mergers & Acquisitions, Debt Restructuring, General Corporate & Commercial. From 2015 until early 2022, she was part of the founding team of Projek57, an award-winning accredited social enterprise which aspires to influence youths from multicultural backgrounds with nation building values, as well as empower the underprivileged. Since April 2022, she rejoined legal practice as the Chief Operating Officer of the law firm of Adnan Sundra & Low where she is able to combine her legal experience with management. She also focuses on exploring ways to enhance the practice of the firm including enhancing efficiency and overall capability and formulating their business strategies.
Reported Earnings • Aug 30First quarter 2024 earnings released: EPS: RM0.067 (vs RM0.11 in 1Q 2023)First quarter 2024 results: EPS: RM0.067 (down from RM0.11 in 1Q 2023). Revenue: RM215.3m (down 28% from 1Q 2023). Net income: RM9.13m (down 39% from 1Q 2023). Profit margin: 4.2% (down from 5.0% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
New Risk • Aug 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: RM457.4m (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (3.0% net profit margin). Market cap is less than US$100m (RM457.4m market cap, or US$99.7m).
Reported Earnings • Jul 30Full year 2023 earnings released: EPS: RM0.24 (vs RM0.69 in FY 2022)Full year 2023 results: EPS: RM0.24 (down from RM0.69 in FY 2022). Revenue: RM1.11b (down 6.3% from FY 2022). Net income: RM33.3m (down 65% from FY 2022). Profit margin: 3.0% (down from 8.0% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Jul 29+ 1 more updateSouthern Acids (M) Berhad, Annual General Meeting, Aug 30, 2023Southern Acids (M) Berhad, Annual General Meeting, Aug 30, 2023, at 14:30 Singapore Standard Time. Agenda: To receive the Audited Financial Statements for the financial year ended 31 March 2023 together with the Reports of the Directors and Auditors thereon. to approve the payment of Single Tier Final Dividend of 5 sen per ordinary share in respect of the financial year ended 31 March 2023; to approve the payment of Directors' fees amounting to RM540,986 for the financial year ended 31 March 2023; to approve the payment of Directors' Benefits up to an amount of RM250,000 for the period from 31 August 2023 until the next AGM of the Company to be held in 2024; to re-elect Mr Chung Kin Mun who is retiring under Clause 113 of the Company's Constitution, and being eligible, has offered himself for re-election; and to transact other business.
お知らせ • Jun 02+ 2 more updatesSouthern Acids (M) Berhad Announces Cessation of Office of Madam Leong So Seh as Member of Nomination and Remuneration CommitteeSouthern Acids (M) Berhad announced cessation of office of Madam Leong So Seh as Member of Nomination and Remuneration Committee with effect from June 1, 2023. Age: 71. Gender: Female. Nationality: Malaysia. Directorate: Independent and Non Executive. Composition of Nomination and Remuneration Committee(Name and Directorate of members after change): Chung Kin Mun (Senior Independent Non Executive Director/Chairman); Tan Sri Datuk Seri Panglima Sulong bin Matjeraie (Independent Non Executive Director/Member); Stephen Wan Yeng Leong (Independent Non Executive Director/Member).
Reported Earnings • May 27Full year 2023 earnings released: EPS: RM0.24 (vs RM0.69 in FY 2022)Full year 2023 results: EPS: RM0.24 (down from RM0.69 in FY 2022). Revenue: RM1.10b (down 6.9% from FY 2022). Net income: RM33.3m (down 65% from FY 2022). Profit margin: 3.0% (down from 8.0% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • May 27+ 2 more updatesOuthern Acids (M) Berhad Recommends Single Tier Final Dividend in Respect of the Financial Year Ended 31 March 2023Southern Acids (M) Berhad recommended a Single Tier Final Dividend of 5.0 sen per ordinary share, amounting to a total payout of RM6,846,706.60 in respect of the financial year ended 31 March 2023. This dividend proposal is subject to the approval by shareholders at the forthcoming Annual General Meeting of the Company.
分析記事 • Mar 03Southern Acids (M) Berhad's (KLSE:SAB) Soft Earnings Are Actually Better Than They AppearSoft earnings didn't appear to concern Southern Acids (M) Berhad's ( KLSE:SAB ) shareholders over the last week. We did...
Reported Earnings • Feb 25Third quarter 2023 earnings released: EPS: RM0.12 (vs RM0.20 in 3Q 2022)Third quarter 2023 results: EPS: RM0.12 (down from RM0.20 in 3Q 2022). Revenue: RM275.9m (down 10% from 3Q 2022). Net income: RM16.8m (down 38% from 3Q 2022). Profit margin: 6.1% (down from 8.8% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 25Second quarter 2023 earnings released: EPS: RM0.082 (vs RM0.13 in 2Q 2022)Second quarter 2023 results: EPS: RM0.082 (down from RM0.13 in 2Q 2022). Revenue: RM280.1m (up 14% from 2Q 2022). Net income: RM11.2m (down 35% from 2Q 2022). Profit margin: 4.0% (down from 6.9% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Price Target Changed • Nov 16Price target decreased to RM3.40Down from RM3.68, the current price target is provided by 1 analyst. New target price is 8.1% below last closing price of RM3.70. Stock is down 2.6% over the past year. The company posted earnings per share of RM0.69 last year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. MD & Non-Independent Executive Director Nick Low was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Nov 01Upcoming dividend of RM0.05 per shareEligible shareholders must have bought the stock before 08 November 2022. Payment date: 28 November 2022. Payout ratio is a comfortable 8.0% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Malaysian dividend payers (5.3%). Lower than average of industry peers (5.6%).
Reported Earnings • Aug 02Full year 2022 earnings released: EPS: RM0.69 (vs RM0.27 in FY 2021)Full year 2022 results: EPS: RM0.69 (up from RM0.27 in FY 2021). Revenue: RM1.18b (up 58% from FY 2021). Net income: RM94.4m (up 153% from FY 2021). Profit margin: 8.0% (up from 5.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Jul 30+ 1 more updateSouthern Acids (M) Berhad Announces Final Dividend, Payable on 28 Nov. 2022Southern Acids (M) Berhad announced a final dividend of MYR 0.0500 per share for the year March 31, 2022. Ex-date is on 08 Nov. 2022 and the Payment date is on 28 Nov. 2022.
お知らせ • May 20Southern Acids (M) Berhad Recommends Single Tier Final Dividend for the Financial Year Ended March 31, 2022Southern Acids (M) Berhad announced that its Board of Directors had recommended a Single Tier Final Dividend of 5.0 sen per ordinary share, amounting to a total payout of MYR 6,846,706.60 in respect of the financial year ended March 31, 2022. This dividend proposal is subject to the approval by shareholders at the upcoming Annual General Meeting of the Company.
Reported Earnings • May 20Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2022 results: EPS: RM0.69 (up from RM0.27 in FY 2021). Revenue: RM1.18b (up 58% from FY 2021). Net income: RM94.5m (up 153% from FY 2021). Profit margin: 8.0% (up from 5.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.2%. Earnings per share (EPS) exceeded analyst estimates by 11%. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Apr 27Price target decreased to RM3.40Down from RM3.68, the current price target is provided by 1 analyst. New target price is 13% below last closing price of RM3.89. Stock is up 3.2% over the past year. The company posted earnings per share of RM0.27 last year.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. MD & Non-Independent Executive Director Nick Low was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 27Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: EPS: RM0.20 (up from RM0.041 in 3Q 2021). Revenue: RM307.2m (up 66% from 3Q 2021). Net income: RM27.2m (up 387% from 3Q 2021). Profit margin: 8.8% (up from 3.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.2%. Earnings per share (EPS) exceeded analyst estimates by 11%. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 29Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: EPS: RM0.13 (up from RM0.06 in 2Q 2021). Revenue: RM246.7m (up 41% from 2Q 2021). Net income: RM17.1m (up 110% from 2Q 2021). Profit margin: 6.9% (up from 4.7% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.2%. Earnings per share (EPS) exceeded analyst estimates by 11%. Earnings per share (EPS) surpassed analyst estimates by 11%. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Sep 22First quarter 2022 earnings released: EPS RM0.17 (vs RM0.13 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: RM258.0m (up 63% from 1Q 2021). Net income: RM23.5m (up 37% from 1Q 2021). Profit margin: 9.1% (down from 11% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Upcoming Dividend • Aug 26Upcoming dividend of RM0.05 per shareEligible shareholders must have bought the stock before 02 September 2021. Payment date: 24 September 2021. Trailing yield: 1.3%. Lower than top quartile of Malaysian dividend payers (4.1%). Lower than average of industry peers (1.8%).
Reported Earnings • Aug 03Full year 2021 earnings released: EPS RM0.27 (vs RM0.23 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: RM745.9m (up 12% from FY 2020). Net income: RM37.4m (up 17% from FY 2020). Profit margin: 5.0% (up from 4.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Price Target Changed • Jul 30Price target decreased to RM3.40Down from RM3.68, the current price target is provided by 1 analyst. New target price is 12% below last closing price of RM3.85. Stock is up 6.6% over the past year.
Reported Earnings • May 28Full year 2021 earnings released: EPS RM0.27 (vs RM0.23 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: RM741.1m (up 11% from FY 2020). Net income: RM37.4m (up 17% from FY 2020). Profit margin: 5.0% (up from 4.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
分析記事 • May 27If You Like EPS Growth Then Check Out Southern Acids (M) Berhad (KLSE:SAB) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
お知らせ • May 26Southern Acids (M) Berhad Recommends Final Dividend for the Year Ended March 31, 2021Board of Directors of Southern Acids (M) Berhad had recommended a Single Tier Final Dividend of 5.0 sen per ordinary share, amounting to a total payout of MYR 6,846,706.60 in respect of the financial year ended 31 March 2021. This dividend proposal is subject to the approval by shareholders at the forthcoming Annual General Meeting of the Company.
分析記事 • Apr 19The Returns At Southern Acids (M) Berhad (KLSE:SAB) Aren't GrowingTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...
Reported Earnings • Feb 27Third quarter 2021 earnings released: EPS RM0.041 (vs RM0.076 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: RM185.6m (up 8.4% from 3Q 2020). Net income: RM5.58m (down 47% from 3Q 2020). Profit margin: 3.0% (down from 6.1% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
分析記事 • Feb 24Are Strong Financial Prospects The Force That Is Driving The Momentum In Southern Acids (M) Berhad's KLSE:SAB) Stock?Most readers would already be aware that Southern Acids (M) Berhad's (KLSE:SAB) stock increased significantly by 6.1...
分析記事 • Jan 13Returns On Capital At Southern Acids (M) Berhad (KLSE:SAB) Paint An Interesting PictureFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
分析記事 • Dec 15What Can We Learn About Southern Acids (M) Berhad's (KLSE:SAB) CEO Compensation?This article will reflect on the compensation paid to Nick Low who has served as CEO of Southern Acids (M) Berhad...
Is New 90 Day High Low • Dec 14New 90-day high: RM3.88The company is up 7.0% from its price of RM3.61 on 15 September 2020. The Malaysian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 35% over the same period.
お知らせ • Nov 27Southern Acids (M) Berhad Announces Appointment of Tan Sri Datuk Seri Panglima Sulong Bin Matjeraie as Independent and Non Executive Ember of Audit CommitteeSouthern Acids (M) Berhad announced appointment of Tan Sri Datuk Seri Panglima Sulong Bin Matjeraie as Independent and Non Executive ember of Audit Committee. Date of change is November 26, 2020.
Reported Earnings • Nov 27Second quarter 2021 earnings released: EPS RM0.06The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: RM174.7m (up 4.7% from 2Q 2020). Net income: RM8.15m (up 6.0% from 2Q 2020). Profit margin: 4.7% (up from 4.6% in 2Q 2020). The increase in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year.
分析記事 • Nov 24Southern Acids (M) Berhad (KLSE:SAB) Share Prices Have Dropped 14% In The Last Three YearsIn order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Is New 90 Day High Low • Nov 17New 90-day high: RM3.80The company is up 3.0% from its price of RM3.70 on 18 August 2020. The Malaysian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 10.0% over the same period.
お知らせ • Sep 26+ 1 more updateSouthern Acids (M) Berhad Announces the Resignation of Encik Teo Leng as Independent and Non Executive Member of Audit CommitteeSouthern Acids (M) Berhad announced the resignation of Encik Teo Leng as Independent and Non Executive Member of Audit Committee. The resignation was effective on September 25, 2020.
Is New 90 Day High Low • Sep 24New 90-day high: RM3.72The company is up 9.0% from its price of RM3.41 on 25 June 2020. The Malaysian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 6.0% over the same period.
Upcoming Dividend • Sep 24Upcoming Dividend of RM0.05 Per ShareWill be paid on the 23rd of October to those who are registered shareholders by the 1st of October. The trailing yield of 1.3% is below the top quartile of Malaysian dividend payers (5.0%), and is lower than industry peers (2.2%).
